Food & Drug Administrations regulatory labeling for semaglutide notes two key facts
For cold-chain deliveries, it is particularly important to arrange redelivery promptly to maintain product integrity
1, plaintiffs must serve expert reports on or before November 18, 2024
Preclinical studies demonstrated that tirzepatide reduced glucose levels during intraperitoneal glucose tolerance tests in wild-type and single incretin receptor-deficient mice to levels comparable to those observed for the GLP-1R agonist semaglutide in Gipr / mice and the DPP-4-resistant analog [d-Ala 2 ]GIP in Glp1r / mice, indicating that the co-agonist is active at both receptors in vivo [84]
Many insurers took a GLP-1-related hit last year, for example, Blue Cross and Blue Shield of Massachusetts recorded losses amounting to nearly $115 million dollars just in the first 3 quarters of 2024, which corresponded with an approximate 250% increase in GLP-1 claims over the same period
It can also cause nausea and vomiting, which can lead to dehydration
